Currently there are four innovative assets in Evestra Onkologia portfolio:
EVE126 – (oral) to treat Endometriosis
EC313 is a novel candidate being developed for gynecological disorders including endometriosis adenomyosis, heavy uterine bleeding, and other disorders.. Developed via structure/activity correlation studies in vitro and in vivo, EC313 demonstrates an optimized ratio between PR-agonistic and PR-antagonistic activities. It is highly effective in humanized in vivo models for endometriosis and fibroids. The oral formulation of EC313, EVE126, is currently under clinical development (Phase I clinical study, completion Q4 2023). This asset is targeting global market valued at $3.9 billion by 2031, growing at a CAGR of 12.6% from 2022 to 2031
EVE132 – EC313 Vaginal Ring to treat Uterine Fibroids
EC313 vaginal ring is a targeted drug delivery to treat uterine fibroids (located within the uterus). Developed by Evestra, EC313 vaginal ring formulation validated in a sheep model, that is a viable animal model to establish proof-of-principle. Targeting marked valued at US$ 5.95 billion globally, by 2028 at 4.4% CAGR
EC359 (oral) to treat a wide range of women’s cancers
EC359 is a rationally designed organic molecule that can emulate the LIF/LIFR binding site, that functions as a first-in class LIFR inhibitor blocking its interactions with multiple ligand. While targeting LIF/LIFR, EC359 action pertains to influence on tumor progression, stemness, therapy resistance, and alterations in tumor microenvironment. This asset is targeting an impressive global oncology drugs market estimated at USD 184.95 billion in 2022. The market is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0% during the forecast period.
EVE134 – Estradiol (E2) Vaginal Ring
E2 commercial formulations are prescribed for large number of indications including moderate to severe vasomotor symptoms and vulvar, vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. Most commercially available formulations include oral tablets, vaginal tablets and transdermal systems. All formulations on the market have significant drawbacks that reduce patient compliance (need for regular intake, short delivery or skin problems at the transdermal delivery site). Evestra E@ vaginal ring is a super-generic of Estring (Pfizer) that delivers E2 for 90 days. Evestra has already demonstrated in vitro 90-day pharmacokinetic equivalency when compared to Estring. . The product targets a hormone replacement therapy market size was valued at USD 21.28 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 6.6% from 2023 to 2030.